Skip to content

New treatment for facial fat loss approved in US

Previous poor adherence and HCV are risk factors for antiretroviral treatment failure

Bevirimat, first maturation inhibitor: tablet formulation provides lower than expected plasma levels

After 48 weeks of study, and 24 weeks in the real world, darunavir continues to show staying power

TB-related immune reaction to HIV therapy occurs 20 months after TB treatment first started - is this a record?

Emergence of resistance mutations: a comparison between drug classes

GSK halts development of new PI, brecanavir

Atazanavir: genetic predictors for hyperbilirubinemia found

Is HIV causing cardiovascular disease by its own effects on cholesterol?